Research programme: atrial fibrillation therapy - Devgen

Drug Profile

Research programme: atrial fibrillation therapy - Devgen

Alternative Names: CDE 5498; Dev 0304

Latest Information Update: 09 Dec 2008

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Devgen
  • Class
  • Mechanism of Action Potassium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Atrial fibrillation

Most Recent Events

  • 05 Nov 2008 Discontinued - Preclinical for Atrial fibrillation in Belgium (PO)
  • 10 Jul 2008 This programme is still in active development
  • 12 Jan 2006 The programme is available for licensing (http://www.devgen.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top